V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 15.4 DKK -6.67% Market Closed
Market Cap: 119.1m DKK
Have any thoughts about
ViroGates A/S?
Write Note

ViroGates A/S
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ViroGates A/S
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Operating Income
-kr13.1m
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Operating Income
kr1.5B
CAGR 3-Years
-16%
CAGR 5-Years
-4%
CAGR 10-Years
3%
Ambu A/S
CSE:AMBU B
Operating Income
kr645m
CAGR 3-Years
24%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Operating Income
kr4.2B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
10%
No Stocks Found

ViroGates A/S
Glance View

Market Cap
119.1m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
3.42 DKK
Overvaluation 78%
Intrinsic Value
Price
V

See Also

What is ViroGates A/S's Operating Income?
Operating Income
-13.1m DKK

Based on the financial report for Sep 30, 2024, ViroGates A/S's Operating Income amounts to -13.1m DKK.

What is ViroGates A/S's Operating Income growth rate?
Operating Income CAGR 5Y
7%

Over the last year, the Operating Income growth was -17%. The average annual Operating Income growth rates for ViroGates A/S have been 12% over the past three years , 7% over the past five years .

Back to Top